This is a working overview of preclinical research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-01. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
The U.S. National Academy of Medicine updated estimated average requirements (EARs) and recommended dietary allowances (RDAs) for vitamin E in 2000. RDAs are higher than EARs so as to identify amounts that will cover people with higher than average requirements. Adequate intakes (AIs) are identified when there is not sufficient information to set EARs and RDAs. The EAR for vitamin E for women and men ages 14 and up is 12 mg/day. The RDA is 15 mg/day. As for safety, tolerable upper intake levels ("upper limits" or ULs) are set for vitamins and minerals when evidence is sufficient. Hemorrhagic effects in rats were selected as the critical endpoint to calculate the upper limit via starting with the lowest-observed-adverse-effect-level. The result was a human upper limit set at 1000 mg/day. Collectively the EARs, RDAs, AIs and ULs are referred to as Dietary Reference Intakes. The European Food Safety Authority (EFSA) refers to the collective set of information as dietary reference values, with population reference intakes (PRIs) instead of RDAs, and average requirements instead of EARs. AIs and ULs are defined the same as in the United States. For women and men ages 10 and older, the PRIs are set at 11 and 13 mg/day, respectively. PRI for pregnancy is 11 mg/day, for lactation 11 mg/day. For children ages 1–9 years the PRIs increase with age from 6 to 9 mg/day. The EFSA used an effect on blood clotting as a safety-critical effect.
==== Member of the Order of the British Empire (MBE) ==== Military Division Royal Navy Chief Petty Officer (Operations) (Radar) Alan James Baker, D077088R. Chief Petty Officer Air Engineering Artificer (L) Stephen Michael Baker, D109087R. Lieutenant Commander Harry Colin Cook. Lieutenant Commander Alan Robert Cronin. Lieutenant Commander Reginald Keith Elsworth. Lieutenant Commander David Michael Foster. Sergeant Steven Paul Goodwin, Royal Marines, P040469W. Lieutenant Commander (SCC) Denise Lilian Gravestock, Royal Navy Reserve. Lieutenant Commander (Acting Commander) Hubert Frederick Hatton. Warrant Officer Peter Robert Jones. Lieutenant Commander Simon John Nicholson Kings. Warrant Officer Michael Stephen Lacey. Warrant Officer Class 1 Peter Lawton, Royal Marines. Lieutenant Commander (now Commander) Christopher Charles Leggett. Lieutenant Commander Anthony Joseph Mawson. Warrant Officer Harold Milne. Lieutenant Commander (now Acting Commander) Geoffrey Charles Pell. Chief Petty Officer (Diver) John Robert Smith, D053657P. Colour Sergeant Alan Keith Turner, Royal Marines, P032549Y. Warrant Officer Nigel Frank Wallace. Lieutenant (now Lieutenant Commander) Geoffrey Ian Woodford. Warrant Officer Simon Yui Kwok Choi. Army The Reverend John Stephen Alker (513792), Chaplain to the Forces (3rd Class), Royal Army Chaplains' Department. Major James Victor Glen Bain (520977), The Argyll and Sutherland Highlanders. 24821742 Corporal Christopher David Ernest Bessey, The Royal Logistic Corps. Lieutenant Russell John Bishop (546098), The Parachute Regiment.
=== Support for 18th Amendment === Bhutto Zardari has repeatedly criticized the historical One Unit Scheme, and warned against any attempt to bring in a presidential system, explaining that it will not be in the interest of democracy. During a press conference on 27 April 2019, he stated that the "presidential system is neither in the interest of the country nor the federation and all democratic forces will resist any such move."
March 4, 2002: Law concerning patients' rights and the quality of the healthcare system. March 4, 2002: Law concerning family names: the concept of patronymic name is replaced by that of family name; father and mother can give their family name to their child, according to different modalities (choice of one or the other, or combination of both in an order they have defined). March 4, 2002: Law concerning parental authority. July 1, 2002: Creation of the Ministry Delegate for Parity and Professional Equality. March 18, 2003: Law for internal security; it includes elements related to passive solicitation, and others creating the "aggravating circumstance of committing a crime or offense due to the victim's sexual orientation." April 11, 2003: Law concerning the election of regional councilors and representatives to the European Parliament, as well as public aid to political parties; rule of alternating candidates of each gender on electoral lists. June 18, 2003: Law concerning the transmission of family names. July 30, 2003: Law reforming the election of senators, which includes elements related to representation and parity. November 26, 2003: Law concerning the control of immigration, the residence of foreigners in France, and nationality. December 18, 2003: Social Security Financing Act for 2004. March 15, 2004: Law regulating, in application of the principle of secularism, the wearing of signs or outfits manifesting religious affiliation in public schools, colleges, and high schools.
Sources: en.wikipedia.org
The cave is quite outstanding and refined, either in terms of architecture and decoration, and departs from the mainstream of other caves at Kizil. Marianne Yaldiz has called it "One of Xinjiang's Mysteries". Untypically, the narrative scenes are placed over the entrance, taking second position to the monumental standing Buddhas of the side wall. This is a layout which became popular farther east in Gansu. In a final narrative evolution, the cave magnifies the figure of the Buddha, and gives an ever smaller role to secondary figures and stories.
Uranium is a chemical element; it has symbol U and atomic number 92. It is a silvery-grey metal in the actinide series of the periodic table. A uranium atom has 92 protons and 92 electrons, of which 6 are valence electrons. Uranium radioactively decays, usually by emitting an alpha particle. The half-life of this decay varies between 159,200 and 4.5 billion years for different isotopes, making them useful for dating the age of the Earth. The most common isotopes in natural uranium are uranium-238 (which has 146 neutrons and accounts for over 99% of uranium on Earth) and uranium-235 (which has 143 neutrons). Uranium has the highest atomic weight of the primordially occurring elements. Its density is about 70% higher than that of lead and slightly lower than that of gold or tungsten. It occurs naturally in low concentrations of a few parts per million in soil, rock and water, and is commercially extracted from uranium-bearing minerals such as uraninite. Many contemporary uses of uranium exploit its unique nuclear properties. Uranium is used in nuclear power plants and nuclear weapons because it is the only naturally occurring element with a fissile isotope – uranium-235 – present in non-trace amounts. However, because of the low abundance of uranium-235 in natural uranium (which is overwhelmingly uranium-238), uranium needs to undergo enrichment so that enough uranium-235 is present. Uranium-238 is fissionable by fast neutrons and is fertile, meaning it can be transmuted to fissile plutonium-239 in a nuclear reactor.
=== Organizational === In management, behaviors are associated with desired or undesired focuses. Managers generally note what the desired outcome is, but behavioral patterns can take over. These patterns are the reference to how often the desired behavior actually occurs. Before a behavior actually occurs, antecedents focus on the stimuli that influence the behavior that is about to happen. After the behavior occurs, consequences fall into place. Consequences consist of rewards or punishments.
Sources: en.wikipedia.org
Carbohydrates: 5 to 15% of the energy consumed Protein: 20 to 30% Fats: 0 to 3% Raw celery and grapefruit are often claimed to have negative caloric balance (requiring more energy to digest than recovered from the food), with the assumption being that the thermic effect exceeds the low caloric content due to the high fibre matrix that must be unraveled to access their carbohydrates. However, there has been no research carried out to test this hypothesis and a significant amount of the thermic effect depends on the insulin sensitivity of the individual, with more insulin-sensitive individuals showing a significant TEF while individuals with increasing resistance have negligible to zero effects. The Functional Food Centre at Oxford Brookes University conducted a study into the effects of chilli peppers and medium-chain triglycerides (MCT) on Diet Induced Thermogenesis (DIT). They concluded that "adding chilli and MCT to meals increases DIT by over 50% which over time may accumulate to help induce weight loss and prevent weight gain or regain". Australia's Human Nutrition conducted a study on the effect of meal content in lean women's diets on the thermic effect of food and found that the inclusion of an ingredient containing increased soluble fibre and amylose did not reduce spontaneous food intake but rather was associated with higher subsequent energy intakes despite its reduced glycaemic and insulinemic effects.
==== Bones ==== Together with [18F]sodium floride, PET for bone imaging has been in use for 60 years for measuring regional bone metabolism and blood flow using static and dynamic scans. Researchers have recently started using [18F]sodium fluoride to study bone metastasis as well.
On June 28, 2017, The Walt Disney Company, ABC's parent company, paid at least US$177 million to settle the lawsuit. Counsel for BPI stated that this was at that time the largest amount ever paid in a media defamation case in the United States. The product is regulated in different manners in various regions. In the US, the product is allowed to be used in ground beef, and it can be used in other meat products such as beef-based processed meats. The use of ammonium hydroxide as an anti-microbial agent is approved by the Food and Drug Administration, and is included on the FDA's list of GRAS (generally recognized as safe) procedures, and is used in similar applications for numerous other food products, including puddings and baked goods. The product is not allowed in Canada due to the presence of ammonia, and is banned for human consumption in the European Union. Some consumer advocacy groups have promoted the elimination of the product or for mandatory disclosure of additives in beef, while others have expressed concerns about plant closures that occurred after the product received significant news media coverage. In December 2018, pink slime was reclassified as "ground beef" by the Food Safety and Inspection Service of the United States Department of Agriculture.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.